FDA Approved Darzalex Faspro
The FDA just approved DARZALEX FASPRO, a new subcutaneous formulation approved in four regimens across five indications, including newly diagnosed, transplant-ineligible and relapsed or refractory multiple myeloma.
As you may know, this news is based on results from the COLUMBA study. This approval makes DARZALEX FASPRO the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma and reduces administration time to approximately three to five minutes.
We issued our news release, which is attached here and available here.
We’re excited to bring this new treatment option to the multiple myeloma community. Many thanks for your continued partnership.
Regional Solutions Director
Healthcare Policy & Advocacy, Strategic Customer Group
Johnson & Johnson